Navigation Links
Cellulosic Biofuels Leader Qteros Adds Key Positions
Date:10/24/2009

Kevin F. McLaughlin appointed Chief Financial Officer and Ralph M. Lerner named Senior Vice President of Commercial Development

Marlborough, Mass. (Vocus) October 23, 2009 -- Massachusetts-based biofuels company Qteros, whose breakthrough Q Microbe™ technology turns biomass into cellulosic ethanol, has welcomed Kevin F. McLaughlin and Ralph M. Lerner to the Qteros leadership team.

Mr. McLaughlin brings 30 years of financial and operating management experience from the high tech, biotech, and education industries.

Mr. Lerner has over 20 years of industry experience in general management, business development, and strategy development and implementation in the global petrochemical and energy industry, with companies including BP and Amoco. Mr. Lerner brings to the company a global perspective, having spent six years in Asia; an in-depth understanding of global commodities markets, and extensive experience in developing innovative commercial arrangements.

"Kevin and Ralph arrive at Qteros at a critical time, and we're confident that their backgrounds and skills will help guide our company through our next stages of development and growth," said Qteros president and CEO Dr. William Frey. "As key members of our dynamic leadership team, they will help us build Qteros into an exceptional commercial success."

Mr. McLaughlin most recently served as Chief Operating Officer and member of the Board of Directors at Aptius Education, Inc., a company he helped cofound, which is focused on the acquisition of companies in the areas of career education, vocational and technical training and licensing, and certification programs. From 1996 through 2007, Mr. McLaughlin was with PRAECIS Pharmaceuticals, where as the company's first Chief Financial Officer he had responsibility for private financings, partnership financings, and the company's IPO and secondary stock offerings. In 2004, Mr. McLaughlin became COO and then President and CEO and member of the Board of Directors of PRAECIS and was responsible for negotiations resulting in the sale of the company to GlaxoSmithKline. Earlier in his career he spent 16 years in senior financial roles at Prime Computer and Computervision Corporation.

"Qteros is a fast-moving company with a solid foundation and a great deal of promise in a next-generation industry," said Mr. McLaughlin. "It's very exciting to join the company as it prepares for significant growth."

Mr. Lerner was most recently Vice President of Ventures and Business support for BP's chemicals business based in Shanghai, China, where he served on the Board of Directors and represented BP's shareholder interests in a large joint venture located outside of Shanghai. Prior to that role, he was based in the Chicago area, as general manager of a $600 million global chemical business with manufacturing facilities in the U.S., Canada, and Europe. Earlier in his career, he served as Vice President of Ventures and Development for BP Chemicals based in Hong Kong and Venture Development Manager for Amoco Corporation, as well as holding positions in finance and engineering.

"Throughout my career, I've led multi-functional teams that were focused on creating value through developing and implementing new strategies, projects, and commercial arrangements -- in businesses with a commodity focus and a global perspective," Lerner said. "Bringing that experience to Qteros, a cutting-edge energy company with national and international ties, allows me to apply my skills in one of today's most exciting industries."

Qteros is a venture-backed company committed to delivering innovative process technologies for clean transportation fuels that reduce greenhouse gas emissions at a price competitive with gasoline. The Qteros scientists and business team are dedicated to producing liquid fuels to achieve a sustainable solution to the world's growing energy needs.

See www.qteros.com for more information. Contact: Patricia Charles, 301-887-1060 x111

# # #

Read the full story at http://www.prweb.com/releases/Qteros/Q_Microbe/prweb3098254.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related biology technology :

1. BP and Verenium Announce Vercipia Biofuels to Advance the Commercialization of Cellulosic Ethanol
2. POET to Outline Cellulosic Ethanol's Present, Future at Brazil's Ethanol Summit 2009
3. Solazyme Testing BlueFire Ethanol Cellulosic Sugars in Its Microalgae Renewable Oil Production Process
4. Research Reinforces Economic, Environmental Benefits of Corn Cobs as Source for Cellulosic Ethanol
5. Genencor Launches Accellerase(R) 1500, Next Step Toward Scale-Up of Cellulosic Ethanol
6. Verenium Announces First Commercial Cellulosic Ethanol Project
7. POET Receives Additional $76 Million in Federal Funding For Commercialization of Cellulosic Ethanol
8. Dartmouth researchers advance cellulosic ethanol production
9. POET Announces That Cellulosic Ethanol Pilot Facility Will Be Operational This Year
10. DuPont and Genencor Create World-Leading Cellulosic Ethanol Company
11. Monsanto Company and Mendel Biotechnology Announce Cellulosic Biofuels Collaboration
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Cellulosic Biofuels Leader Qteros Adds Key Positions 
(Date:12/8/2016)... ... December 08, 2016 , ... ... flexible packaging for their exceptionally efficient human mesenchymal stem/stromal cell (hMSC) expansion ... of bioprocess media products engineered to radically streamline culture processes, minimize processing ...
(Date:12/8/2016)... , Dec. 8, 2016  HedgePath Pharmaceuticals, ... that discovers, develops and plans to commercialize innovative ... shares of common stock were approved for trading ... begin trading on the OTCQX, effective today, under ... for the OTCQX market, companies must meet high ...
(Date:12/7/2016)... ... December 07, 2016 , ... ACEA Biosciences, Inc. ... and expansion clinical trial for its lead drug candidate, AC0010, at the World ... trial was to determine the safety, antitumor activity, and recommended phase II dosage ...
(Date:12/7/2016)... /PRNewswire/ - Zenith Capital Corp. ("Zenith" or the "Company") announces webcast ... the Company,s Annual and Special Meeting. The ... on Thursday, December 15, 2016 at Mount Royal ... 4825 Mount Royal Gate SW, Calgary, Alberta ... and management information circular, containing the matters to be considered ...
Breaking Biology Technology:
(Date:12/2/2016)... Dec. 1, 2016   SoftServe , a ... BioLock , an electrocardiogram (ECG) biosensor analysis system ... key IoT asset. The smart system ensures device-to-device ... steering wheel and mobile devices to easily ,recognize, ... As vehicle technology advances, so too must ...
(Date:11/29/2016)... VILNIUS, Lithuania , Nov. 29, 2016 ... high-precision biometric identification and object recognition technologies, ... kit (SDK) for fingerprint recognition solutions that ... extract a fingerprint template using less than ... used in compact devices that have limited ...
(Date:11/22/2016)... According to the new market research report "Biometric ... Signature, Voice), Multi-Factor), Component (Hardware and Software), Function (Contact and Non-contact), Application, ... is expected to grow from USD 10.74 Billion in 2015 to reach ... and 2022. Continue Reading ... ...
Breaking Biology News(10 mins):